Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 3/20 | 0.65 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | KCNMA1 | Q12791 | 4/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL251067 | 0.80 | PSMB8 (0.67) | PSMB8CNR1CNR2KCNMA1PARP1 | |
| SCHEMBL3888532 | 0.79 | PSMB8 (0.65) | PSMB8 | |
| SCHEMBL9173518 | 0.79 | PSMB8 (0.65) | PSMB8KCNMA1PARP1 | |
| SCHEMBL248854 | 0.75 | NOS1 (0.39) | PSMB8PARP1NOS1BACE1AXL | |
| SCHEMBL29755094 | 0.75 | NOS1 (0.39) | PSMB8PARP1NOS1BACE1AXL | |
| SCHEMBL23449132 | 0.72 | PSMB8 (0.41) | PSMB8 | |
| SCHEMBL9394277 | 0.72 | PSMB8 (0.56) | PSMB8KCNMA1PARP1 | |
| SCHEMBL1701339 | 0.72 | PARP1 (0.53) | PARP1NOS1BACE1AXL | |
| SCHEMBL30166992 | 0.72 | NPC1 (0.50) | PSMB8NOS1BACE1AXLAHR | |
| SCHEMBL17276019 | 0.72 | NUDT1 (0.51) | BACE1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313832-B1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-02-24 | — | — | EP | disclosed |
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
| US-10221163-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180244656-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MLX, ZFX, MMP12 | PSMB8 1621/4885CNR1 3728/4885CNR2 4634/4885 |
| US-10221163-B2 | Metallo-beta-lactamase inhibitors | MLX, ZFX, MMP12 | PSMB8 1490/4885CNR1 3799/4885CNR2 4641/4885 |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MLX, ZFX, MMP12 | PSMB8 1621/4885CNR1 3728/4885CNR2 4634/4885 |
| US-20180244656-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MLX, ZFX, MMP12 | PSMB8 1490/4885CNR1 3799/4885CNR2 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.